Table II.
Clinicopathological features in a PTC series according to the BRAF mutation status.
| Variable | BRAFV600E (n=19) | BRAF wild type (n=25) | P-value |
|---|---|---|---|
| Age, years (SD) | 54.6 (17.9) | 51.1 (15.0) | 0.100 |
| Tumor size, cm (SD) | 2.1 (1.1) | 2.6 (1.7) | 0.100 |
| Multifocal tumor, n (%) | 7 (41.1) | 8 (38.0) | 0.800 |
| Bilateral tumor, n (%) | 4 (23.5) | 5 (23.8) | 1.000 |
| Positive margin status, n (%) | 15 (83.3) | 13 (61.9) | 0.200 |
| Lymphovascular invasion, n (%) | 5 (26.3) | 9 (42.8) | 0.200 |
| Perineural invasion, n (%) | 1 (5.2) | 0 (0.0) | 0.400 |
| Extrathyroid extension, n (%) | 10 (52.6) | 2 (9.5) | 0.009a |
| Lymph nodes metastases, n (%) | 11 (57.8) | 5 (23.8) | 0.028a |
| Advanced stage (III/IV), n (%) | 14 (73.6) | 9 (42.8) | 0.049a |
| Persistent.disease, n (%) | 6 (31.5) | 3 (14.2) | 0.300 |
| Disease.free survival, n (%) | 11 (57.8) | 18 (85.7) | 0.100 |
a
Significant values (P.0.05). PTC, papillary thyroid carcinoma; SD, standard deviation; BRAF, B.Raf proto.oncogene.